RENO, Nev., May 12, 2005 (PRIMEZONE) -- Martin Nutraceuticals Inc.'s (Pink Sheets:MTNU) Director of Research and Development, Dr. A. W. Martin, is pleased to announce results of recent clinical trials of Oxygenol(tm) in the aid of Chronic Fatigue Syndrome and Fibromyalgia.
Oxygenol(tm) is a proprietary blend of antioxidants with many health benefits. In the study, Oxygenol(tm) was given to patients suffering from Chronic Fatigue Syndrome and Fibromyalgia. These two conditions are characterized by extreme fatigue and cognitive symptoms which include sleep disorder, short term memory loss, concentration difficulties, widespread musculoskeletal aches, pain and stiffness and soft tissue tenderness.
Dr. Martin states, "Fibromyalgia is a symptom of the greater complex of Chronic Fatigue Syndrome -- one that perhaps should be considered a sister ailment."
The test patients were given 200 mg daily of Oxygenol(tm) in a 6-week period. In this amount of time, over 3/4 of the patients showed that 85% of all cognitive symptoms were decreased and remarkably 1/4 of these cases showed over 95% improvement of all cognitive symptoms with the use of Martin Nutraceuticals Oxygenol(tm). The tests that were used included Short Term Memory Testing using recall and concentration, as well as Cognitive Testing.
Dr. Martin attributes these findings to Oxygenol's ability to cross the blood brain barrier and increase micro circulation to the brain. "Oxygenol's efficacy is what makes it a fantastic product, one that we anticipate will prosper in a market that does more than $1 billion in annual sales," concurs Dr. Martin.
Dr. Martin is a Canadian nutritional researcher and author of several books including "Chronic Fatigue Syndrome: the Modern Women's Curse."
Martin Nutraceuticals' Oxygenol(tm) will be available in exclusive retail outlets by the third quarter of this year.
Forward-Looking Statements
The management of the company, who take full responsibility for its content, prepared this press release. Statements in this news release concerning the company's business outlook or future economic performance, anticipated profitability, revenues, expenses, or other financial items, and statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements" as that term is defined under the Federal Securities Laws. Forward-looking statements are subject to risks, uncertainties and other factors which could cause actual results to differ materially from those contained in such statements. Such risks, uncertainties and factors include, but are not limited to, future capital needs, changes and delays in product development plans and schedules, customer acceptance of new products, changes in pricing or other actions by competitors, and general economic conditions.